Bispecific antibody targeting CD155 mediates T-cell immunotherapy against human gynecological malignancies [0.03%]
双特异抗体靶向CD155介导T细胞免疫治疗人妇科恶性肿瘤
Li Ma,Juan Ma,Dingqing Feng et al.
Li Ma et al.
T cells are crucial regulators in cancer treatment due to their cytotoxic ability. Recently, immunotherapies based on bispecific antibodies (Bi-Ab) have achieved remarkable effects in cancer treatment, attributed to their capability of recr...
US FDA-accelerated approvals and subsequent withdrawals: influence on Japanese clinical oncology practice guidelines [0.03%]
美国FDA加速批准及后续撤回对日本临床肿瘤实践指南的影响
Hayase Hakariya,Akihiko Ozaki,Tetsuya Tanimoto
Hayase Hakariya
The US (US) Food and Drug Administration (FDA)-accelerated approval pathway facilitates early access to oncology drugs based on surrogate endpoints, with required confirmatory post-marketing trials. However, regulatory decisions vary global...
Rare exon 18 G719A and exon 21 L833V compound EGFR mutations show favorable response to Third-Generation TKI Furmonertinib: A case report and literature review [0.03%]
稀有 exon 18 G719A 和 exon 21 L833V 复合 EGFR 突变对第三代 TKI Furmonertinib 显示出良好的反应：病例报告及文献回顾
Yuejian,Jijun Zhao,Tao Wu et al.
Yuejian et al.
EGFR exon 19 deletions and exon 21 point mutations are the most common mutations in lung adenocarcinoma, with patients deriving significant clinical benefits from EGFR tyrosine kinase inhibitors (TKIs). However, the efficacy of TKIs in rare...
Correction to: Clinical research progress of fruquintinib in the treatment of malignant tumors [0.03%]
Corrigendum: 厄喹替尼临床研究在恶性肿瘤治疗中的进展
Shihao Zhao,Wenhui Wang,Jingyi Li et al.
Shihao Zhao et al.
Published Erratum
Investigational new drugs. 2025 Mar 19. DOI:10.1007/s10637-025-01519-6 2025
Evaluation of the anti-leukemia activity and underlying mechanisms of the novel perinucleolar compartment inhibitor CTI-2 in acute myeloid leukemia [0.03%]
新型核周 compartments 抑制剂 CTI-2 在急性髓系白血病中的抗白血病活性及其潜在机制的评估
Anran Li,Mingmin Yu,Yue Zhao et al.
Anran Li et al.
Acute myeloid leukemia (AML) is a malignant clonal hematological tumor originating from immature myeloid cells and is the most prevalent type of leukemia in adults. Traditional chemotherapy regimens based on cytarabine and anthracycline age...
Clinical features, treatment, and prognosis of nivolumab induced immune encephalitis [0.03%]
纳武单抗引起免疫性脑炎的临床特征，治疗和预后
Zhaoquan Wu,Haibo Lei,Ronghui Li et al.
Zhaoquan Wu et al.
Immune encephalitis (IE) is an immune-mediated adverse events (irAEs) linked to nivolumab therapy, and its clinical characteristics remain unclear. This study aimed to analyze the clinical patterns of nivolumab-induced IE to inform diagnosi...
First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma [0.03%]
首个人体，一期剂量递增研究的SL-279252，一种六聚物PD1-Fc-OX40L融合蛋白，在晚期实体瘤和淋巴瘤患者中的应用
Melissa Johnson,David Hong,Irene Braña et al.
Melissa Johnson et al.
SL-279252 is a bifunctional hexameric fusion protein adjoining the extracellular domains of PD-1 and OX40L via an inert IgG4 derived Fc domain. A Phase 1 dose escalation study was conducted in patients (pts) with advanced solid tumors or ly...
From development to clinical success: the journey of established and next-generation BTK inhibitors [0.03%]
从研发到临床成功：已上市与下一代BTK抑制剂的历程
Shivani Gupta,Arpit Sharma,Alok Shukla et al.
Shivani Gupta et al.
Over the past decade, Bruton's tyrosine kinase (BTK) has emerged as a pivotal therapeutic target for B-cell malignancies and autoimmune diseases, given its essential role in B-cell development and function. Dysregulation of BTK signalling i...
Retrospective analysis of clinical features of nivolumab-induced immune-related pancreatitis [0.03%]
尼伏鲁单抗引起免疫介导胰腺炎的临床特征的回顾分析
Yong Pan,Wei Li,Zhaoquan Wu et al.
Yong Pan et al.
To study the clinical features of nivolumab-induced immune-related pancreatitis and to provide evidence for its recognition and treatment. Cases of nivolumab-induced pancreatitis were collected by searching Chinese and English databases unt...
A novel anti-HER2/EGFR bispecific antibody-drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs [0.03%]
新型抗HER2/EGFR双特异性抗体药物偶联物表现出有前景的抗肿瘤功效并克服了对HER2或EGFR靶向ADC的耐药性
Huoying Huang,Yuxin Zhou,Chengzhang Shang et al.
Huoying Huang et al.
HER2 and EGFR are frequently co-expressed in various tumors. While antibody-drug conjugates (ADCs) targeting HER2, such as T-DM1 and T-Dxd, have shown remarkable antitumor effects in clinical responses, their effectiveness is constrained by...